MBRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MB

Mkt Cap

$5.7M

Volume

1.17M

Next Earnings

November 12th

Loading chart

MB

MBRXMoleculin Biotech, Inc.

MBRX

Pay with—

Available Balance0.00

MB

Mkt Cap

$5.7M

Volume

1.17M

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular MedicineMoleculin Biotech announced the publication of a peer-reviewed cardiac safety analysis of Annamycin in Frontiers in Cardiovascular Medicine. A pooled analysis of five clinical trials involving 90 patients found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits, with independent evaluation by Cleveland Clinic supporting continued clinical development.GlobeNewswire Inc. · Sep 28, 2026

Scalable Biotech Manufacturing Unlocks a $14B MarketThe global cell therapy manufacturing market is projected to reach $14 billion by 2035, driven by over 1,000 active clinical candidates. FDA regulatory flexibility is accelerating timelines for cell and gene therapy approvals. Several biotech companies are advancing scalable manufacturing capabilities and clinical programs: Avaí Bio is producing Master Cell Banks for α-Klotho therapy; ImmunityBio validated scalable NK cell manufacturing; Fate Therapeutics achieved outpatient CAR T-cell therapy for autoimmune diseases; Fractyl Health completed pivotal trial randomization for GLP-1 weight maintenance; and Moleculin Biotech enrolled its 45th subject in a Phase 2B/3 AML trial.Benzinga · Mar 27, 2026

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE StudyMoleculin Biotech (MBRX) released a CEO Corner segment discussing progress on its pivotal Phase 3 MIRACLE Study evaluating Annamycin combined with cytarabine for relapsed or refractory acute myeloid leukemia. The adaptive trial includes an initial cohort of 45 patients with interim unblinding planned after treatment completion. Enrollment and dosing are progressing as planned, building on encouraging results from the earlier MB-106 Study.GlobeNewswire Inc. · Mar 11, 2026

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsightOver 100 pharmaceutical companies are actively developing 150+ pipeline drugs for Acute Myeloid Leukemia (AML), with approximately 10 drugs in late-stage development and 50+ in mid and early stages, focusing on targeted therapies and personalized treatment approaches.GlobeNewswire Inc. · Dec 4, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)Moleculin reported positive results from a Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases. The trial showed improved overall survival and progression-free survival, with a clinical benefit rate of 59.4%.GlobeNewswire Inc. · Jun 4, 2025

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand ConferenceMoleculin Biotech, a late-stage pharmaceutical company, presented its top five reasons for why investors should pay attention to the company in 2025, including updates on its lead drug candidate Annamycin and other pipeline programs.Benzinga · Mar 11, 2025

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International SymposiumMoleculin Biotech, Inc. announced that its abstract has been accepted for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium. The abstract focuses on the company's drug candidate Annamycin, which is in development for the treatment of relapsed or refractory acute myeloid leukemia (AML).Benzinga · Mar 3, 2025

Moleculin Participates in Virtual Investor "What This Means" SegmentMoleculin Biotech, a late-stage pharmaceutical company, announced that its CEO Walter Klemp participated in a Virtual Investor segment to discuss the progress of the company's Phase 3 pivotal trial evaluating Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) patients.Benzinga · Jan 27, 2025

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026Moleculin Biotech announced progress in the development of its drug candidate Annamycin for the treatment of acute myeloid leukemia (AML), including positive Phase 2 data and an upcoming pivotal Phase 3 trial.Benzinga · Jan 8, 2025

Bitget Wallet Expands DeSci Ecosystem AccessBitget Wallet, a leading Web3 non-custodial wallet, has expanded its features to provide users access to Decentralized Science (DeSci) ecosystems. Users can now access a hot token list, real-time market insights, and a dedicated dApp zone for DeSci projects, enabling them to discover, trade, and participate in emerging DeSci initiatives.GlobeNewswire Inc. · Dec 26, 2024

to start trading

MB

MBRXMoleculin Biotech, Inc.

MBRX

Pay with—

Available Balance0.00

Your PositionYou don't own any MBRX yet.

Related Tickers

Earnings